Synonyms: | |
Status: | Phase 3 |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N06AG02 |
UNII: | PJ0Y7AZB63 |
InChI Key | YHXISWVBGDMDLQ-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C13H17ClN2O2 |
Molecular Weight | 268.74 |
AlogP | 1.4 |
Hydrogen Bond Acceptor | 3.0 |
Hydrogen Bond Donor | 1.0 |
Number of Rotational Bond | 4.0 |
Polar Surface Area | 41.57 |
Molecular species | NEUTRAL |
Aromatic Rings | 1.0 |
Heavy Atoms | 18.0 |
Action | Mechanism of Action | Reference |
---|---|---|
INHIBITOR | Monoamine oxidase A inhibitor | Other |
Primary Target | |
---|---|
Monoamine oxidase A |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Oxidoreductase
|
- | 3900-10700 | - | 1080-100000 | 7-95 | |
Ion channel
Voltage-gated ion channel
Potassium channels
Voltage-gated potassium channel
|
- | 79433 | - | - | - | |
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Serotonin receptor
|
- | - | 5012 | - | - | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 2 |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Depressive Disorder | 4 | D003866 | ClinicalTrials |
Dementia | 3 | D003704 | ClinicalTrials |
Schizophrenia | 3 | D012559 | ClinicalTrials |
Anxiety | 3 | D001007 | ClinicalTrials |
Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
Tobacco Use Disorder | 2 | D014029 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 71320-77-9 |
ChEBI | 83531 |
ChEMBL | CHEMBL86304 |
DrugBank | DB01171 |
DrugCentral | 1825 |
EPA CompTox | DTXSID9040554 |
FDA SRS | PJ0Y7AZB63 |
Human Metabolome Database | HMDB0015302 |
Guide to Pharmacology | 7428 |
PharmGKB | PA452615 |
PubChem | 4235 |
SureChEMBL | SCHEMBL49708 |
ZINC | ZINC000019606670 |